A new concept in cancer care: The supportive care program by Esper, Peg et al.
Abstract
This article describes the findings of
a pilot program designed to enter
advanced prostate cancer patients into
the hospice benefit while they are still
being actively treated, but in situations
where treatment is known to be primari-
ly palliative in nature. The supportive
care program (SCP) combines the med-
ical model’s goal to prolong life with the
goal of hospice to palliate symptoms
and improve quality of life (QOL). The
concept of a SCP was developed to cre-
ate a team approach where advanced
prostate cancer patients who are start-
ing investigational chemotherapy are
concurrently enrolled into a hospice
program. The objectives were to identi-
fy whether SCP improved QOL and
continuity of care while remaining cost-
effective. Data were collected on pa-
tient quality of life, performance status,
use of health care resources, and costs
for the 36 enrolled patients. A compar-
ison was made to a matched set of 23
control patients. Our findings indicate
that the SCP contributes to continuity of
care while being cost-effective.
Introduction
Over the years, two separate models
have existed to care for patients with
advanced malignancies. The first
model, or the traditional medical
model, has its focus on the prolonga-
tion of life by the use of various
known and investigational agents. The
second model, the hospice model,
focuses on the palliation of symptoms
in people with terminal illness who
are believed to have a life expectancy
of six months or less.1 While these two
models of care appear to be at oppos-
ing ends of the spectrum, critical com-
monalties exist between them. This
overlap of goals has led to the devel-
opment of a model of care referred to
as the supportive care program (SCP),
which is the topic of this article.
Prostate cancer is first in male can-
cer incidence and second only to lung
cancer in cancer deaths in US men. Of
the estimated 184,500 new cases in
1998, 20 percent of those patients will
be diagnosed with metastatic disease.
Approximately 39,000 patients with
advanced prostate cancer will die
from their disease this year.2 Once a
patient has been diagnosed with
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metastatic disease, there is no known
curative therapy. The standard treat-
ment of disease at this stage is hor-
monal ablative therapy. This therapy
is effective in a large percentage of
patients with advanced prostate can-
cer, but is only a temporary measure.
Most patients will have evidence of
recurrent disease in approximately 18
months.3 Following failure of hor-
monal treatment (hormone refractory
prostate cancer), the choice becomes
enrollment in a clinical trial, use of
treatments with some track record of
efficacy, alternative therapies, or sup-
portive care measures. 
To date, treatments utilized follow-
ing hormonal therapy have failed to
demonstrate any significant impact on
survival. As a result, additional end-
points such as quality of life (QOL)
have been examined to help determine
whether or not therapy has any benefit
in this population.4 Patients at this
stage who elect to undergo treatment
with chemotherapeutic agents are sub-
ject to a multitude of potential side
effects and toxicities, such as myelo-
suppression, mucositis, nausea and
vomiting, and anorexia. In addition,
these patients suffer the symptoms
frequently associated with their dis-
ease process, which can include pain,
difficulty with urination, and fatigue.5
Patients undergoing treatment are
generally seen in the outpatient clinic
at frequent intervals to monitor their
response to treatment as well as evalu-
ation of side effects and toxicities
resulting from therapy. Eventually,
however, treatments fail and a time
comes when no further treatment is
feasible. This is frequently the time
when hospice referrals are made.
Referral to hospice at this point can
be very disconcerting for both health
care providers and patients and their
families. The frequent clinic visits dur-
ing treatment normally lead to close
bonds developing between patients and
the clinical staff providing care. Once
hospice care is instituted, the clinic visits
are infrequent or even absent, creating
a sense of abandonment on the part of
the patient and family. The clinical staff
also feels a sense of loss as this individ-
ual, in whom they have personally
invested, will no longer be under their
immediate care.
From the hospice vantage point,
there is also frustration. Hospice staff
generally includes nurses, health-aides,
social workers, and others who function
as a team to support patients and their
families in the dying process. While
physical symptom management is a pri-
ority, much attention is given to the psy-
chosocial and spiritual aspects of the
dying process. The median length of
stay (LOS) found in most hospices is 36
days.6 One can imagine the difficulty
hospice staff has in trying to establish
relationships with patients and families
that enable them to address such deli-
cate issues effectively in this brief time
frame. Many hospice staff members
feel that they end up doing little more
than “crisis intervention.” Financially,
the situation for the hospice is also less
than optimal. As has been well docu-
mented, the last two weeks of life are
the most expensive for the majority of
patients.7 Given that this becomes the
major time period in which patients are
enrolled in hospice, the cost-effective-
ness of care provided by the organiza-
tion is frequently in question.
Hospice staff members are experts at
symptom management and in dealing
with psychosocial issues related to ter-
minal illness. The concept of a support-
ive care model was developed to try and
create a “win-win” situation in which
the critical skills of hospice staff could
be combined with those of the acute
care staff in a “team approach” that
would allow what we have referred to
as a “transitionless” model of care. In
this model, patients who are considered
to be “hormone refractory” and are
starting investigational or salvage treat-
ments are concurrently enrolled into a
hospice program. Hospice staff be-
comes a team with the acute care
providers in helping to manage the
patients’ side effects and symptoms
from treatment at home, while they
begin to address issues related to termi-
nal illness with the patient and family.
The acute care staff has frequent contact
with the hospice staff from the begin-
ning, making the eventual move to
complete hospice support less distress-
ing for everyone involved. Patients and
their caregivers have been able to
develop relationships with hospice
staff. As a result, they do not view the
move to total hospice support as aban-
donment. A diagrammatic representa-
tion of this model is found in Figure 1.
The intent of developing the SCP
transitionless model was to provide
care for patients with advanced prostate
cancer that would eliminate abandon-
ment, enhance QOL and quality care by
beginning hospice support earlier in the
course of terminal illness, and be cost-
effective for the hospice, acute care
facility, and third-party payors.
Objectives and purpose
Our objective was to identify if
enrollment in a hospice program during
active treatment for metastatic hormone
refractory prostate cancer would:
• improve quality of life for these
patients;
• provide improved management
of side effects and toxicities as-
sociated with treatment;
• provide cost-effective versus cost-
prohibitive care;
• improve continuity of care be-
tween the acute care facility and
home hospice staff.
Literature review
The need for improved end-of-life
(EOL) care has become recognized as
a critical social issue over the past five
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to 10 years. A significant awareness of
inadequacies in EOL care was made in
the report of the SUPPORT project
(Study to Understand Prognoses and
Preferences for Outcomes and Risks of
Treatment). A total of 9,015 adult
patients in five US teaching hospitals
were involved in this study. Reported
shortcomings in EOL care included
deficits in communication between
physicians and patients, where only 47
percent of physicians were aware of
their patients preference to avoid CPR.
An alarming 38 percent of the patients
who died had documented stays of at
least 10 days in intensive care units,
where they underwent multi-invasive
procedures. Even more disturbing were
reports that pain levels were moderate
to severe at least half the time in 50 per-
cent of conscious patients.8
While the need for improved EOL
care is evident, there continue to be
questions as to how best to deliver this
care. Much has been published related
to the need for improved education and
training in EOL care for health care
providers.9,10 Both medicine and nurs-
ing have identified a lack of education
in their initial training in this area.11
However, few programmatic meth-
ods for improving EOL care are
reported in the literature. A report by
Ferrell et al., discusses the develop-
ment of a training program to help
nurses take an active role in pain man-
agement for hospital patients. This
program is intended to improve pain
management via the interventions
received, as needed, by the “prn” nurs-
es.12 Another program designed by the
Oregon Health Sciences University is
called, the comfort care team. This
interdisciplinary team provides con-
sultative services primarily for hospi-
talized, seriously ill patients with
comfort care needs. The services
include pain management as well as
psychological, spiritual, and symptom
management support. The consulta-
tive team is available Monday through
Friday, 8:00 am to 5:00 pm. Patients
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are not required to be terminal for
referrals to be made.13
Another concept, termed “Medi-
caring,” has been proposed, which
suggests that EOL care is best facili-
tated in a managed care capitated set-
ting. The benefit of such a system is
felt to be the provision of access to the
desired elements of palliative care
within the managed care structure.14
Admittedly, an identified concern with
this type of program is the fear that
participating physicians would face
ethical dilemmas as they make deci-
sions about how much care is too
much and what services or procedures
are too high in cost and not beneficial
from an incentive perspective.
Another issue addressed in the lit-
erature concerns the cost of both hos-
pice and EOL care. Multiple studies
have attempted to identify costs of
care accurately at the end of life. It has
been suggested that hospice can save
between 25 percent and 40 percent of
costs during the last month of life.15
However, this figure drops to between
0 and 10 percent, if the last 12 months
of life are considered.
Bloom and Amenta compared the
costs of hospice care for study patients
to the comparable cost if the same
patients had had the alternative of
hospital and nursing home care. The
authors reported an estimated savings
of almost four million dollars.7 There is
still considerable debate on what the
real savings potential would be, if any,
when patients were enrolled into the
hospice benefit sooner rather than later.
Several studies attribute this problem to
the fact that median lengths of stay in
many hospice programs are extremely
short. In a study of 6,451 hospice
patients by Christarkis and Escarce, the
median LOS was found to be 36 days
with over 15 percent of patients dying
within seven days of enrollment.
Multiple potential causes of this limited
LOS have been theorized with a fre-
quent reference to the fear physicians
have in inaccurately estimating the
Medicare-prescribed “six months or
less” prognosis for patients.6
The topic of this article, then, pro-
vides a new dimension to the current
literature and adds to the body of
knowledge in EOL care by its multidi-
mensional evaluation of providing
early hospice care to patients still
receiving therapeutic treatment for an
incurable malignancy. An evaluation
of physical, psychosocial, and finan-
cial elements of care utilizing matched
controls is discussed to help determine
the feasibility of pursuing such a pro-
gram on a larger scale.
Methods and procedure
During the period from September
1995 through August 1997, a total of
36 men with hormone refractory pro-
state cancer were enrolled into the
hospice SCP. The concept of the pro-
gram was introduced to patients in the
outpatient clinic during a regularly
scheduled visit by the oncologist or
oncology nurse practitioner, generally
at the time patients were going to be
starting a new treatment for their can-
cer. A convenience sample was ob-
tained as patients were presented with
the concept of the program and auto-
matically enrolled if they agreed.
Those patients who agreed to partici-
pate were introduced to the SCP coor-
dinator who was jointly employed by
the Comprehensive Cancer Center
where patients were receiving care as
well as the hospice participating in
this program. The coordinator would
spend additional time with patients
reviewing the program and arrange a
time for a home visit with the hospice
staff to do a “formal” admission to the
hospice program. From this point,
patients were jointly cared for by the
cancer center and hospice staff.
The SCP coordinator played a vital
role in the program by handling all
communication to hospice staff regard-
ing clinic visits (medication changes,
schedule for lab draws, tests, treatment
changes, and treatment response, etc.).
The SCP coordinator also reported nur-
sing assessments made to the acute care
providers at the cancer center. The hos-
pice home-care nurses would directly
contact the physician or nurse practi-
tioner for order changes or acute prob-
lems, but relied on the SCP coordinator
for transfer of routine information re-
garding patient and family issues to the
Cancer Center staff.
Hospice staff assessed the needed fre-
quency for home visits. This was gener-
ally more frequent in the very beginning,
decreased in frequency during stable
phases of treatment and increased when
patients were experiencing symptom
management difficulties or in the final
stages of their illness. All of the various
services that hospice has to offer were
available to the SCP patients.
Patients were seen for regularly
scheduled visits by their oncologist in
keeping with protocol or standard care
requirements. Charges for treatment,
clinic visits, medications, professional
fees, diagnostic studies, etc., were
billed to hospice as long as they were
related to the patients diagnosis of
prostate cancer.
If patients were experiencing prob-
lems, attempts were made to have
them evaluated first by the hospice
staff at home. The hospice nurses
would go to the home, assess the prob-
lem, and report back to the oncology
team at the cancer center to avoid
unnecessary trips to the clinic or
emergency room. Patients who re-
quired hospitalization for acute treat-
ment, symptom control, or respite
were admitted to the cancer center’s
inpatient hospice beds.
In an effort to demonstrate what dif-
ference, if any, a program of this nature
makes, a control group was established.
The control group for this project con-
sisted of 23 patients who were concur-
rently identified as having hormone
refractory prostate cancer during this
same time interval and undergoing simi-
lar treatment. Some of the control group
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were patients who had not been interest-
ed in the program when presented it.
The majority of patients in the control
group, however, lived outside the geo-
graphic range of services for the hospice
participating in this project. The average
age for SCP patients was 72, while the
control group’s average age was 67. The
study followed patients for approxi-
mately six months (180 days) with an
average of 162 days for the SCP
patients, as compared to 166 days for
control patients. In terms of response to
treatment, 30 percent of SCP patients
had a therapeutic response to therapy
(decrease in amount of disease), while
22 percent of the control patients
demonstrated a positive response to
treatment. Table 1 summarizes demo-
graphic data for the two groups.
For both the enrolled (SCP) and
control groups, information was col-
lected on the financial costs of care,
clinic visits, emergency room visits,
unscheduled visits, hospital admis-
sions, treatment received, laboratory
work, PSA (prostate specific antigen)
values, length of stay in program,
performance status, pain scores, and
QOL measurement. The financial staff
of the cancer center and hospice
worked together to track the costs asso-
ciated with care. Data were initially
kept in Excel spreadsheet files and, at
the time of review, were exported to
SPSS 7.5 files for statistical analysis.
Medical care costs have become a
recent focus of research, especially
during the last year of life. Some 27
percent of annual Medicare expendi-
tures are for services delivered within
this time frame.16 Accordingly, one
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Table 1. Demographics
Conventional care (n = 23) Palliative care (n = 36)
Characteristics Number % Number %
Age, in years
< 57 2 8.7 4 11.1
57 - 64 6 26.1 4 11.1
65 - 71 11 47.8 6 16.7
> 71 4 17.4 22 61.1
Mean age (years) 67 72
Race
White 22 96 29 80.5
Black 1 4 7 19.5
Deaths 2 9 9 25
Range LOS (days) 90 - 180 90 - 180
Mean LOS (days) 166 162
Chemotherapy
IV 17 74 10 27.9
PO (oral) 6 26 25 69.4
none 0 1 2.7
OP (out patient) diagnostic 
procedures
19 82.6 13 36
Performance status
0 (90 - 100)* 16 69.6 14 38.9
1 (70 - 80)* 7 30.4 16 34.4
2 (60)* 0 0 6 16.7
* Karnofsky scale
objective of this pilot study was to
evaluate the impact of intervention on
the cost from a societal perspective. All
except one of the patients in the inter-
vention group were enrolled into the
Medicare Hospice Benefit. The control
group consisted of 17 (74 percent) with
standard Medicare coverage, 5 (22 per-
cent) with Blue Cross/ Blue Shield
(BC/BS), and 1 (4 percent) with other
insurer coverage. For this selection of
patients, Medicare expenditures were
used as a proxy for cost. Medical
expenditures in both the intervention
(Hospice Benefit) and control (stan-
dard Medicare) were calculated as
standard Medicare reimbursement. We
did not look at the expenditures of
Hospice of Michigan, the hospice pro-
viding the home-care services.
Costs for the outpatient facility’s
services were determined by using a
cost-to-charge ratio based upon facili-
ty charges.17 Medicare fee-screen
reimbursement for billed codes (CPT-4)
(current procedural terminology) was
used as a proxy for professional costs
and Medicare reimbursement by DRG
(diagnosis related group) was the
basis for hospitalization costs. Facility
costs include intravenous chemothera-
py and, in order to capture oral chemo-
therapy, costs were derived from the
index of wholesale drug prices.18
Patients were tracked prospectively
for laboratory tests, procedures, hos-
pitalizations, chemotherapy, clinic
visits, transfusions, radiation therapy,
emergency room visits, and response
to chemotherapy.
The selection of a time frame for
cost comparisons in previous end-of-
life studies have limitations. Com-
parisons can be over too short of a time
span for adequately evaluating cost
differences. In studies comparing hos-
pice versus conventional care re-
viewed by Emanuel, costs over longer
time periods resulted in smaller sav-
ings.15 The design of this pilot study
compares costs over six months, start-
ing at the initiation of chemotherapy.
The analysis of outcome and process
measurements, including cost,
depends on data collection that is con-
sistent in both groups. Therefore, we
enrolled patients into the hospice
program with metastatic prostate can-
cer at a fixed time period when pa-
tients start to receive chemotherapy
and ended at 180 days, death, or com-
pletion of the study.
Charts were reviewed prospective-
ly to obtain data on visit history,
admissions, PSA values, etc. Patients
were asked to provide a pain score
using a linear analog scale of 1 to 10 at
each visit. Karnofsky performance-
status evaluation was recorded at each
visit as well. Quality-of-life assess-
ment was made utilizing the Func-
tional Assessment of Cancer Therapy
Prostate (FACT-P).
The Functional Assessment of
Cancer Therapy—General (FACT-G)
is a 34-item, generic, quality-of-life
measurement tool, which was devel-
oped by Cella and colleagues. The
instrument measures four cornerstone
dimensions of quality of life: physical
well-being (PWB), social/family well-
being (SWB), emotional well-being
(EWB), and functional well-being
(FWB). FACT-G also includes a brief
(two-item) assessment of the individ-
ual’s relationship with his or her doc-
tor (RWD). The prostate-specific sub-
scale was added to the FACT-G in
1993 to include questions specific to
the quality of life in men with prostate
cancer, resulting in what is now
referred to as the FACT-P. The relia-
bility and validity of the FACT-G and
FACT-P, used in this study, are well
established.19,20 The instrument is
written at a sixth-grade reading level
and is available in eight languages. All
of the data reported were collected
using the English form. The FACT-P
takes approximately eight to 10 min-
utes to complete. Version 3 of the
FACT-P was utilized for all patients
participating in this study. Version 4 is
now available for use. It differs from
Version 3 in that the “Relationship
With Doctor” subscale has been deleted.
This two-question subscale was asso-
ciated with a ceiling effect and pro-
duced little variability in the data.
Also, global quality-of-life questions at
the end of each subscale that were never
used in the scoring of the instrument
have been deleted. Item numbering has
also been changed to universal alphanu-
meric codes. The prostate-specific sub-
scale has remained unchanged. 
Results
Data on a total of 36 SCP and 23
control patients were used to evaluate
the desired outcomes of this study.
The two groups were quite similar in
relation to mean age and mean length
of stay. In the supportive care pro-
gram, 80.5 percent of participants
were Caucasian with 19.5 percent
African American, as compared to the
control group, where 96 percent of the
participants were Caucasian with only
four percent African American (Table
1). During the analysis period, 25 per-
cent of the patients in the supportive
care program died, while only 8.7 per-
cent of the control group died.
The two groups varied in baseline
performance status as well. Sixty-nine
percent of the control patients had a per-
formance status of 90 to 100, while only
39 percent of the SCP patients were in
this range. Overall, the performance of
the SCP patients at baseline was signifi-
cantly less than that of the control group
(chi square=7.14, p < .03).
Resource utilization was also eval-
uated. Numbers overall were small
and, as a result, no statistical analysis
was feasible. Table 2 shows the vari-
ous services utilized by the two
groups. Though no substantive state-
ments can be made regarding these
figures, note that the overall number
of visits per SCP participant was less
than that of the control group (5.9 ver-
sus 6.9). Considering the lower per-
formance status of the SCP group as a
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whole, one would have expected those
patients to require more frequent visits
for problem intervention. 
The cost comparison of the interven-
tion versus the control group shows an
overall savings of $2,736 over six
months. This figure is calculated from
the average cost per day of $43.50.
However, in comparing the medical
treatment of the two groups, the treat-
ment modalities employed must be con-
sidered. Control patients had higher
performance status and received IV
chemotherapy (74 percent, control, ver-
sus 28 percent, SCP) at a higher per-
centage. Oral chemotherapy is less
toxic and does not demand the number
of diagnostic tests to monitor patients as
compared with IV chemotherapy. Both
the chemotherapy and diagnostic tests
could contribute to an increase in cost.
Hospice home care cost was not in-
cluded in this analysis and will be
assessed in future projects. Cost analy-
sis is presented in Table 2.
Finally, quality-of-life evaluation
used comparisons between a baseline
FACT-P score and two subsequent
readings at one month post-initiation
of treatment and the third score
between three and six months post-
initiation of treatment. Of the 59
patients on which data were collected,
only 37 had complete QOL data for
analysis. Some data were not avail-
able due to incomplete surveys, sur-
veys being lost, or spouses completing
them instead of the patient. Of those
that could be evaluated for QOL mea-
surement, 24 were enrolled in the SCP
and 13 were control patients.
No statistically significant changes
were noted in either the general FACT,
the prostate-specific subscale, or total
FACT-P scores at any of the three
points in time. Of note, however, is
that our experience in past studies
with prostate cancer patients on clini-
cal trials with this instrument has been
that scores have generally decreased
at the first month for the majority of
patients.21 This has been attributed to
the onset of side effects and toxicities
associated with treatment. This was
true for the control group in relation to
the FACT score at time point 1.
However, the SCP patients actually
saw an increase in all three scores at
the one-month time point. We believe
that the support patients received from
hospice staff may have had a positive
effect on them, which prevented this
drop from occurring, but the numbers
are too small to demonstrate significant
differences. The route of chemotherapy
administration was significantly differ-
ent between groups with fewer patients
in the SCP group receiving IV chemo-
therapy (p < .04). Despite this, note that
there still were no significant differ-
ences in QOL scores, tending to suggest
that therapies did not significantly alter
QOL, regardless of whether they were
administered intravenously or not.
Table 4 summarizes mean QOL scores
for both groups.
Limitations of analysis
An obvious limitation of this study
was the sampling technique utilized.
As a convenience sample, we lacked
the strength in reporting findings that
a randomized sample would provide.
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Table 2. Cost analysis
Itemized costs









OP (out patient) facility cost 48,304 2,100 52,858 1,461
IV chemotherapy* 120,531 7,090 72,861 7,286
OP (out patient) chemotherapy† 3,738 623 15,894 611
IP (in patient) DRG 22,496 979 88,802 2,467
Professional cost 25,137 1,093 34,476 958
Total cost 220,170 9,573 264,612 7,350
Average cost per day per patient 58.70 43.50
* IV chemotherapy for controls (n = 17) and for SCP (n = 10); † PO chemotherapy for controls (n = 6) and for SCP (n = 26)
The study and control groups were
matched reasonably well with the
exception of the route of administra-
tion of therapy and initial performance
status. There may have been a bias to
enroll patients in the program who
would not be treated as aggressively,
or patients with a lower performance
status were more likely to be willing to
participate in this type of program. Our
goal in the future is to enroll patients
earlier during the more aggressive
treatment phase and follow the transi-
tion to palliative and supportive med-
ical intervention up to the time of death
and including the bereavement phase.
Data collected through these transi-
tions will be needed to evaluate cost-
effectiveness. The pilot study’s cost
analysis supports the hypothesis that
the intervention group will not cost
more than those receiving convention-
al medical care.
Another limitation of the study
was the small number of patients for
evaluation, particularly in regard to
QOL data. The numbers did not pro-
vide adequate power to generalize
findings. As this was a pilot study,
however, to analyze data as soon as
possible was important to be certain
that there were no significant nega-
tive effects as a result of this program
from the perspective of either patient
care or cost.
Other limitations included the
inability to track pain management
adequately in the control group pa-
tients, making comparison to the
enrolled group impossible. This
would have been valuable information
to report. The other major weakness in
this study was the lack of evaluation
of caregiver response to enrollment in
the SCP. While the verbal feedback
was very positive, we did not have
systems in place to measure caregiver
burden in the two groups. Along that
same perspective, the effect of the
program on hospice staff and acute
care staff was obtained in an anecdotal
fashion only, and therefore not accu-
rately reportable. The study also had
the limitation of being confined to
prostate cancer patients, making gen-
eralization to patients with other
malignancies more difficult. The nar-
row focus was important, though, in
this initial pilot study.
Discussion and
implications for practice
As primary caregivers involved
with the care of advanced prostate
cancer patients, we found the support-
ive care program concept to be very
positive. Our ability to provide in-
creased continuity of care for patients
was evident to us, despite the inability
of the data to reflect this adequately.
To have knowledgeable staff in the
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Table 3. Health care services
Conventional care Palliative care
Health services N Total N Total
Ambulatory care visits 23 158 36 214
Unscheduled visits 6 8 5 5
ER visits 4 5 3 3
Hospital days 6 35 9 67
Transfusions 3 6 7 14
Radiation therapy 3 3 1 1
Home health aide visits N/A 36 305
LPN visits N/A 36 381
RN visits N/A 36 507
Social worker visits N/A 36 231
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Table 4. Quality of life scores




FACT baseline 24 56 111 82 15.57
FACT time 1 24 62 112 84 14.65
FACT time 2 22 47 112 79 18.2
PROSTATE baseline 24 11 42 29 7.49
PROSTATE time 1 24 14 40 30 8.19
PROSTATE time 2 22 13 43 29 7.11
TOTAL FACT baseline 24 67 146 111 21.28
TOTAL FACT time 1 24 76 152 114 20.83
TOTAL FACT time 2 22 60 155 107 22.65
Control
FACT baseline 13 57 97 81 11.96
FACT time 1 13 61 101 80 11.76
FACT time 2 13 61 104 82 13.61
PROSTATE baseline 13 16 37 28 6.8
PROSTATE time 1 13 11 39 29 7.26
PROSTATE time 2 13 10 42 29 7.75
TOTAL FACT baseline 13 73 134 108 17.78
TOTAL FACT time 1 13 72 134 109 16.61
TOTAL FACT time 2 13 81 146 111 19.19
* FACT - Functional Assessment of Cancer Therapy - General Measure
PROSTATE - Prostate specific subscale
TOTAL - Combined FACT and PROSTATE scores
home has been extremely helpful to
assist in managing the side effects of
treatment once patients begin therapy
and then to be able to work with the
same staff in supporting the patient
and family during the final days of
life. For those of us involved, a sense
of “team” developed along with in-
creased trust in each other’s abilities
to provide quality patient care.
We expected to see a more signifi-
cant difference in QOL scores for
those patients enrolled in the SCP.
Perhaps, the measurement tool was
not capable of capturing the changes
that we perceived to be taking place.
The use of a symptom distress scale,
for instance, might have been a useful
adjunct to the FACT-P instrument.
Of major concern was the fear that
this program would prove to be finan-
cially burdensome to one or more of
the parties involved. While the SCP
actually appeared to be a more cost-
effective means of delivering care at
this stage, the significant differences
in route of administration of therapy
and lack of randomization of the sam-
ple must be considered in the overall
evaluation. Still, the increased length
of stay for hospice patients seemed to
alleviate some of the “major hit” that
hospice programs take when patients
are admitted to the hospice benefit
during the final “crisis of death.” 
The concept of a SCP has proven to
be worth pursuing further in our initial
pilot study. Plans are underway to
expand the program to include several
disease sites, including one non-can-
cer terminal illness, and to conduct the
next trial as a randomized multi-insti-
tutional study. These plans also
include more in-depth cost analysis,
more comprehensive QOL measure-
ment (including a caregiver burden
survey), and general satisfaction sur-
veys at timed intervals.
The need for more patient-focused
end-of-life care is real. The SCP pro-
gram is one way of helping to increase
the resources available to patients and
families who are entering this stage of
illness without causing a negative eco-
nomic effect on society. The ability to
move patients from the therapeutic
treatment stage to pure palliation of
symptoms in a “transitionless” fash-
ion is certainly a concept that requires
further investigation. Our initial find-
ings, however, provide support for
expanding and further exploring the
potential benefits of this type of pro-
gram for patients, families, and health
care providers alike.
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